Studies indicate that the CareAdvantage Perioperative Efficiency approach yielded improvements for hip and knee procedures that led to an estimated annual cost savings of >$262,000.
FDA accepted DiscGenics’ Investigational New Drug Application for a clinical study of its cell therapy product candidate to treat degenerative disc disease.
Spineology commenced full market release of the Eliteâ„¢ Expandable Interbody Fusion system. More than 300 cases have been completed since limited launch in 2Q16.Â